NCT01724320Unknown1 期
A Phase I, First-in-man Study of OTX008 Given Subcutaneously as a Single Agent to Patients With Advanced Solid Tumors
Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)3 个研究点 分布在 2 个国家目标入组 20 人开始时间: 2012年2月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 发起方
- 入组人数
- 20
- 试验地点
- 3
- 主要终点
- Dose Limiting Toxicity
研究概览
简要总结
The purpose of this study is to determine the recommended dose (RD) for further phase II studies, of the Galectin-1 inhibitor OTX008 given subcutaneously in patients with advanced solid tumors
详细描述
Overexpression of galectin-1 protein is well documented in different types of cancers, with associated bad prognostic and enhanced metastases spreading.
In-vitro/in-vivo preclinical studies showed that OTX008 inhibits galectin-1 expression. In different cancer models in animals, OTX008 reduced tumor growing and metastases spreading and it was observed a blood vessels architecture normalization.
Thus, OTX008 appears to be an innovating approach to treat cancers and this clinical phase I study aims to evaluate OTX008 therapy in patients with advanced solid tumors.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Signed informed consent prior to beginning protocol specific screening procedures. Patients registered in this trial must be treated and followed at the participating centers. Patients should receive the study treatment within 7 days after registration
- •Histologically proven malignant solid tumor
- •Patients having failed all standard therapies, or for whom standard therapies are deemed ineffective or contra-indicated.
- •Patients aged > 18 years.
- •ECOG performance status (PS) of 0 to 1
- •Off previous systemic therapy (except LH-RH agonist therapy started > 2 months prior to study entry that could be continued) , radiation therapy, or surgery for at least 30 days prior to first study treatment administration (45 days for bicalutamide).
- •Recovery from the toxic effects of prior treatment to NCIC-CTC grade < 1, except alopecia
- •Adequate bone marrow function including: Neutrophils >= 1.5 x 10E9 /L; platelets >= 100 x 10E9 /L, Hb > 8g/dL without transfusion.
- •Creatinine clearance >= 60 mL/min (Cockroft & Gault formula, or MDRD formula for patients aged > 65 years).
- •Adequate LFTs: Total bilirubin < 1 x the institutional upper normal limits (UNL); ALAT/ASAT >= 3 x UNL (or >= 5 x UNL in case of liver metastases).
- •Serum albumin > 28g/L.
- •Availability of the last tumor imaging within 6 months prior to baseline tumor imaging
- •Availability of archived pathology specimen (paraffin-embedded block) from the tumor
排除标准
- •History of prior malignancy other than those previously treated with a curative intent more than 5 years ago and without relapse (any tumor) or basal cell skin cancer, in situ cervical cancer, superficial bladder cancer, or high grade intestinal polyps treated adequately, regardless of the disease-free interval.
- •Pregnant or lactating women or women of childbearing potential not using adequate contraception. Male patients not using adequate contraception.
- •Tumor sites that necessitate immediate intervention (supportive care, surgery or radiation therapy) such as symptomatic brain or leptomeningeal tumor, spinal cord compression, other compressive tumor masses, painful bone metastasis, bone fracture, etc...
- •Other serious illness or medical conditions, which, in the investigator's opinion could jeopardize patient's safety or hamper understanding of the study by the patient, patient's compliance to study treatment, or interpretation of study results. These conditions include (but are not restricted to):
- •Congestive heart failure or angina pectoris not medically controlled. Previous history of myocardial infarction within 1 year from study entry, uncontrolled hypertension or arrhythmias.
- •Existence of significant neurologic or psychiatric disorders impairing the ability to obtain consent.
- •Active infection.
- •Concurrent treatment with other experimental therapies or participation in another clinical trial within 30 days prior to first study treatment administration.
- •Concurrent treatment with any other anticancer therapy (except LH-RH agonist therapy initiated > 2 months prior to study entry).
研究组 & 干预措施
OTX008
Experimental
Single-arm study of OTX008 given subcutaneously, daily without interruption to patients with advanced solid tumors. Starting dose: 65 mg/day.
干预措施: OTX008 (Drug)
结局指标
主要结局
Dose Limiting Toxicity
时间窗: up to 3 weeks of OTX008 treatment
Dose Limiting Toxicity (DLT) will be assessed during the first 21 days (3 weeks)of OTX008 treatment in each patient to determine Recommended Dose (RD)
次要结局
- Pharmacokinetics (PK)(Days 1, 2 and 22 of OTX008 treatment)
- Pharmacodynamics (PD)(Days 1 and 22 of OTX008 treatment)
研究者
研究点 (3)
Loading locations...
相似试验
已完成
1 期
A Study of JNJ-67856633 in Participants With Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)Leukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-HodgkinNCT03900598Janssen Research & Development, LLC226
招募中
1 期
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma or Previously Treated Amyloid Light-chain (AL) AmyloidosisRelapsed or Refractory Multiple MyelomaPreviously Treated Amyloid Light-chain (AL) AmyloidosisNCT05652335Janssen Research & Development, LLC180
进行中（未招募）
1 期
A Study of JNJ-88998377 for Relapsed/Refractory B-cell Non-Hodgkin's LymphomaLymphoma, Non-HodgkinRefractory B-Cell NHLRelapsed B-cell NHLNCT06470438Janssen Research & Development, LLC58
撤回
1 期
A Study Assessing tOTX015 in Combination With Azacitidine (AZA) or AZA Single Agent in Patients With Newly-diagnosed Acute Myeloid Leukemia (AML) Not Candidate for Standard Intensive Induction Therapy (SIIT)Acute Myeloid LeukemiaNCT02303782Oncoethix GmbH, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
已完成
1 期
A Study of JNJ-63898081 in Participants With Advanced Stage Solid TumorsNeoplasmsNCT03926013Janssen Research & Development, LLC40